Abstract: Objective To investigate the expression of nucleotide excision repair cross complementary gene 1（ERCC1），thymidylate synthetase gene（TYMS） and nucleotide reductase M1（RRM1） in cervical cancer and their relationship with clinicopathological feactures and chemotherapy effect. Methods The clinical data of 33 patients with cervical cancer diagnosed by pathology from January 2016 to December 2016 were collected. The expression of ERCC1，TYMS and RRM1 mRNA in cervical cancer tissues was detected by RT-PCR，and the relationship between ERCC1，TYMS and RRM1 mRNA，clinicopathological features and chemotherapy effect were analyzed. Results The positive rates of ERCC1，TYMS and RRM1 in 33 cases of cervical cancer tissues were 78.8%，69.7% and 75.8%，respectively. The expression of ERCC1 was related to FICG stage，tumor size，high-risk HPV infection，lymphangio-vascular tumor thrombus，myometrial invasion depth，squamous cell carcinoma antigen（SCC-Ag）（P<0.05）； the expression of TYMS was related to tumor size，high-risk HPV infection，lymphangio-vascular tumor thrombus（P<0.05）； the expression of RRM1 was not related to clinicopathological features（P>0.05）. The expression of ERCC1 and TYMS mRNA was positive correlated（r=0.608， P=0.004）. The total effective rate of ERCC1，TYMS and RRM1 positive patients were lower than those of negative patients（P<0.05），and the 3-year overall survival rate were lower than those of negative patients，but the difference was not statistically significant（P>0.05）. Conclusions The patients with ERCC1，TYMS or RRM1 positive expression in cervical cancer have poor chemotherapy effect.

Key words: Cervical cancer, Nucleotide excision repair cross complementary gene 1, Thymidine synthase gene, Nucleotide reductase M1, Chemotherapy